EU/3/05/261: Orphan designation for the treatment of non-infectious uveitis affecting the posterior segment of the eye

Fluocinolone acetonide

Table of contents

Overview

On 7 March 2005, orphan designation (EU/3/05/261) was granted by the European Commission to Bausch & Lomb (UK) Ltd, United Kingdom, for fluocinolone acetonide (prolonged-release intravitreal implant) for the treatment of non-infectious uveitis affecting the posterior segment of the eye.
The sponsorship was transferred to Bausch & Lomb Ireland in October 2006.

Key facts

Active substance
Fluocinolone acetonide
Intended use
Treatment of non-infectious uveitis affecting the posterior segment of the eye
Orphan designation status
Positive
EU designation number
EU/3/05/261
Date of designation
07/03/2005
Sponsor
Bausch & Lomb Ireland
IDA Industrial Park
Waterford
Ireland
Telephone: + 353 51 35 501
Telefax: + 353 51 35 56 39
E-mail: waterfordinfo@bausch.com

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

Related content

How useful was this page?

Add your rating
Average
2 ratings